MedTrace Logo

Gardasil Versus Cervarix in the Treatment of Warts

NCT05383625 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2022-05-20

No results posted yet for this study

Summary

Warts are common, benign, epidermal proliferations caused by HPV infecting skin and mucous membranes. Treatment of warts poses a true challenge despite existing variable therapeutic modalities, whether destructive or immunotherapeutic. Human papilloma virus (HPV) vaccines are FDA approved for the prevention of genital warts and wart related precancerous and cancerous lesions but they are not indicated for treatment of preexisting warts yet

Conditions

  • Verruca Viral

Interventions

DRUG

Quadrivalent Human Papillomavirus (Types 6,11,16,18) Recombinant Vaccine

intralesional 0.1 ml every two weeks

DRUG

Bivalent Human Papilloma Virus Vaccine

Intralesional 0.1 ml every two weeks

DRUG

Saline

intralesional into the largest warts every two weeks

Sponsors & Collaborators

  • Zagazig University

    lead OTHER_GOV

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-09-01
Primary Completion
2021-10-01
Completion
2021-12-01
FDA Drug
Yes

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05383625 on ClinicalTrials.gov